{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:45:32Z","timestamp":1780411532383,"version":"3.54.1"},"reference-count":8,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,8]]},"DOI":"10.1182\/blood.2023022796","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T16:34:52Z","timestamp":1707410092000},"page":"475-476","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["The quest for a cure in follicular lymphoma"],"prefix":"10.1182","volume":"143","author":[{"given":"Sanne H.","family":"Tonino","sequence":"first","affiliation":[{"name":"Amsterdam University Medical Centers (location University of Amsterdam, Cancer Center Amsterdam)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-3802","authenticated-orcid":false,"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Centers (location University of Amsterdam, Cancer Center Amsterdam)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2024020816343666300_bib1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2024020816343666300_bib2","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41375-022-01535-y","article-title":"Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era","volume":"36","author":"Dinnessen","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2024020816343666300_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41408-021-00574-5","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018","volume":"11","author":"Dinnessen","year":"2021","journal-title":"Blood Cancer J"},{"issue":"23","key":"2024020816343666300_bib4","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024020816343666300_bib5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024020816343666300_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2024020816343666300_bib7","doi-asserted-by":"crossref","first-page":"S447","DOI":"10.1016\/S2152-2650(23)01349-6","article-title":"IBCL-098 TRANSCEND FL: phase II study results of lisocabtagene maraleucel (Liso-Cel) in patients with R\/R follicular lymphoma (FL)","volume":"23","author":"Nastoupil","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2024020816343666300_bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14737140.2023.2171994","article-title":"A\u00a024-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"23","author":"Palomba","year":"2023","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/6\/475\/2211212\/blood_bld-2023-022796-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/6\/475\/2211212\/blood_bld-2023-022796-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T16:34:57Z","timestamp":1707410097000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/6\/475\/514775\/The-quest-for-a-cure-in-follicular-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,2,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022796","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]}}}